| No information available. |
Summary of Clinical Use ![]() |
| Batoclimab (HBM9161; IMVT-1401) was a clinical candidate for a range of autoimmune conditions. Despite meeting the primary endpoint in a phase 3 myasthenia gravis trial, the developer (Immunovant) chose to cease development of batoclimab, instead replacing it with a second generation anti-FcRn option (imeroprubart; IMVT-1402) as lead asset. Imeroprubart failed to provide significant clinical benefit in a phase 2 proof-of-concept trial in cutaneous lupus erythematosus (CLE) [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05581199 | To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP | Phase 2 Interventional | Immunovant Sciences GmbH | ||
| NCT05524571 | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease | Phase 3 Interventional | Immunovant Sciences GmbH | ||
| NCT05403541 | Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis | Phase 3 Interventional | Immunovant Sciences GmbH | ||
| NCT05039190 | Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients | Phase 3 Interventional | Harbour BioMed (Guangzhou) Co. Ltd. | ||
| NCT04428255 | A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP | Phase 2/Phase 3 Interventional | Harbour BioMed (Guangzhou) Co. Ltd. | ||
| NCT03971916 | A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers | Phase 1 Interventional | Harbour BioMed (Guangzhou) Co. Ltd. | 2 | |
| NCT05517447 | Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease | Phase 3 Interventional | Immunovant Sciences GmbH | ||